The emergence of PPM1D mutations is associated with prior exposure to specific DNA-damaging agents as it has been shown for TP53. 25 Indeed, PPM1D mutations provide a survival advantage onto hematopoietic clones by rendering them resistant to apoptosis and confer to HSC resistance to chemotherapy leading to expansion during cancer treatment. The gene discussed is TP53; the disease is cancer.